Swiss pharmaceutical firm Novartis and computer giant Microsoft have signed a five-year partnership deal aimed at transforming the Basel-based pharma’s business - from finance to manufacturing - using artificial intelligence.
This content was published on
1 minute
Keystone-SDA/sb
The new Novartis AI innovation lab, with Microsoft as its strategic AI and data-science partner, aims to “significantly bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide”, the two firms said in a statement on TuesdayExternal link.
Joint research activities will be carried out at the Novartis Campus in Basel, Switzerland, at the Novartis Global Service Center in Dublin, Ireland, and at the Microsoft Research Lab in Cambridge, Britain.
They hope to start focusing on personalized therapies for macular degeneration, cell & gene therapies and drug design.
Novartis Chief Executive Officer Vas Narasimhan said, “As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend lives. Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world.”
More
More
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
Various heads of state confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
Swiss study: insects mainly migrate at midday and dusk
This content was published on
A study led by the Swiss Ornithological Institute in canton Lucerne is helping to better understand the movement patterns of migratory insects.
Red Cross: 22 staff killed in Middle East since October
This content was published on
The Red Cross and Red Crescent network in Gaza and Israel has lost 22 staff members since last October, the Swiss Red Cross (SRC) said on Wednesday.
Dortmund’s Kobel is first Swiss goalie in Champions League final
This content was published on
Borussia Dortmund’s Gregor Kobel has achieved history by becoming the first Swiss goalkeeper to reach a Champion’s League final.
University students in Switzerland join Gaza protest wave
This content was published on
Pro-Palestinian activists occupied university buildings in Lausanne, Geneva and Zurich on Tuesday, widening the protest movement in the Alpine nation.
TradeXBank to resume full operations after Sberbank Switzerland taken off sanctions list
This content was published on
TradeXBank, the former Swiss branch of Russia’s Sberbank, will be able to resume its dollar-denominated activities from the second half of this year.
Geneva decides not to remove controversial memorials
This content was published on
The city of Geneva has presented an action plan regarding a series of controversial local statues and monuments of historical figures linked to racism, colonialism or slavery.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis rejects suspected data manipulation in US
This content was published on
Swiss pharma giant Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to US authorities.
WHO adopts watered-down resolution on drug transparency
This content was published on
The World Health Organization (WHO) has adopted a resolution to improve transparency on drug prices but some people say it doesn't go far enough.
This content was published on
Swiss pharmaceutical Novartis must face a US government lawsuit accusing it of paying millions of dollars in kickbacks to doctors.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.